LY-3039478

Generic Name: LY-3039478

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₃F_₃N_₄O_₄

CAS Number: 1421438-81-4

Unique Ingredient Identifier: 923X28214S

Background: LY3039478 has been used in trials studying the treatment and basic science of LYMPHOMA, Neoplasms, Solid Tumor, COLON CANCER, and BREAST CANCER, among others.

Clinical Trials

Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Biological: BB2121
Drug: CC-220
Drug: BMS-986405

First Posted Date: 2021-04-22

Last Posted Date: 2025-05-15

Lead Sponsor: Celgene

Target Recruit Count: 21

Registration Number: NCT04855136

Locations: 🇺🇸
Local Institution - 109, Hackensack, New Jersey, United States
🇺🇸
Local Institution - 114, Chicago, Illinois, United States
🇺🇸
Local Institution - 108, Boston, Massachusetts, United States

and more 14 locations

A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma

Phase 1

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: CC-99712
Drug: BMS-986405

First Posted Date: 2019-07-29

Last Posted Date: 2024-01-30

Lead Sponsor: Celgene

Target Recruit Count: 160

Registration Number: NCT04036461

Locations: 🇺🇸
Local Institution - 102, Seattle, Washington, United States
🇺🇸
Local Institution - 104, Dallas, Texas, United States
🇨🇦
Local Institution - 202, Toronto, Ontario, Canada

and more 17 locations

A Study of the Absorption, Distribution, Metabolism and Excretion of LY3039478 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3039478

First Posted Date: 2016-09-28

Last Posted Date: 2017-01-10

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 8

Registration Number: NCT02917733

Locations: 🇺🇸
Covance Clinical Research Inc, Madison, Wisconsin, United States

Study of LY3039478 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3039478
Drug: 3C 15N 2H-LY3039478 IV

First Posted Date: 2016-09-20

Last Posted Date: 2017-01-25

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 12

Registration Number: NCT02906618

Locations: 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Leeds, United Kingdom

A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumor

Interventions: Drug: LY3039478

First Posted Date: 2016-07-19

Last Posted Date: 2024-01-11

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 11

Registration Number: NCT02836600

Locations: 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kashiwa, Chiba, Japan

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Soft Tissue Sarcoma
Colon Cancer
Solid Tumor
Breast Cancer
Cholangiocarcinoma

Interventions: Drug: LY3039478
Drug: LY3023414
Drug: Abemaciclib
Drug: Taladegib
Drug: Cisplatin
Drug: Gemcitabine
Drug: Carboplatin

First Posted Date: 2016-05-27

Last Posted Date: 2020-08-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 94

Registration Number: NCT02784795

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States

and more 8 locations

A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL

Phase 1

Completed

Conditions: T-cell Acute Lymphoblastic Leukemia
T-cell Lymphoblastic Lymphoma

Interventions: Drug: LY3039478
Drug: Dexamethasone
Drug: Placebo

First Posted Date: 2015-08-07

Last Posted Date: 2019-09-11

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 36

Registration Number: NCT02518113

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
University of Texas MD Anderson, Houston, Texas, United States
🇺🇸
City of Hope National Medical Center, Duarte, California, United States

and more 8 locations

A Study of LY3039478 in Participants With Advanced Cancer

Phase 1

Completed

Conditions: Neoplasms
Lymphoma
Neoplasm Metastasis

Interventions: Drug: LY3039478
Drug: Prednisone

First Posted Date: 2012-09-27

Last Posted Date: 2018-08-07

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 237

Registration Number: NCT01695005

Locations: 🇺🇸
University of Miami School of Medicine, Miami, Florida, United States
🇺🇸
Columbia University Medical Center, New York, New York, United States
🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom

and more 3 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy